Manufacturer of Controlled Substances; Notice of Application, 62873 [E7-21849]

Download as PDF Federal Register / Vol. 72, No. 215 / Wednesday, November 7, 2007 / Notices Dated: October 31, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–21849 Filed 11–6–07; 8:45 am] DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on October 9, 2007, Noramco Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule pwalker on PROD1PC71 with NOTICES Codeine-N-Oxide (9053) .............. Morphine-N-Oxide (9307) ............. Amphetamine (1100) .................... Methylphenidate (1724) ................ Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Morphine (9300) ........................... Thebaine (9333) ........................... Opium, raw (9600) ....................... Opium poppy (9650) .................... Oxymorphone (9652) ................... Alfentanil (9737) ........................... Sufentanil (9740) .......................... Carfentanil (9743) ......................... Fentanyl (9801) ............................ I I II II II II II II II II II II II II II II II II 16:14 Nov 06, 2007 Jkt 214001 Dated: October 31, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–21850 Filed 11–6–07; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE DEPARTMENT OF LABOR Drug Enforcement Administration Office of the Secretary Manufacturer of Controlled Substances; Notice of Registration Data Users Advisory Committee; Establishment By Notice dated June 26, 2007, and published in the Federal Register on July 3, 2007 (72 FR 36483), Penick Corporation, 33 Industrial Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: In accordance with the provisions of the Federal Advisory Committee Act, and after consultation with the General Services Administration, I have determined that the establishment of a Data Users Advisory Committee to replace the former Business Research Advisory Council and Labor Research Advisory Council is in the public interest in connection with the performance of duties imposed on the Department of Labor. The Committee will advise the Commissioner of Labor Statistics regarding the statistical and analytical work of the Bureau of Labor Statistics, providing perspectives on these programs from the points of view of data users from various sectors of the U.S. economy, including the labor, business, research, academic, and government communities. The Committee will not exceed 25 members. Membership and participation in the Committee and any subcommittees may be from, and are intended to be broadly representative of, the labor, business, research, academic and government communities in the United States. Membership of the Committee represents a balance in terms of the points of view represented. Membership will consist of an equal number of labor and business representatives, the total number of which is not to exceed 16. The Committee will function solely as an advisory body and in compliance with the provisions of the Federal Advisory Committee Act. The Charter will be filed with the Library of Congress and the appropriate congressional committees. Interested persons are invited to submit comments regarding reestablishment of the Data Users Advisory Committee. Such comments should be addressed to: Michael D. Levi, Associate Commissioner, Office of Publications and Special Studies, Bureau of Labor Statistics, Department of Labor, Postal Square Building, 2 Massachusetts Avenue, NE., Drug Schedule Cocaine (9041) ............................. Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Diphenoxylate (9170) ................... Ecgonine (9180) ........................... Hydrocodone (9193) ..................... Morphine (9300) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... The company plans to manufacture small quantities of the Schedule I controlled substances for internal testing; the Schedule II controlled substances will be manufactured in bulk for distribution to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administrator, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than January 7, 2008. VerDate Aug<31>2005 62873 II II II II II II II II II II II The company plans to manufacture the listed controlled substances as bulk controlled substance intermediates for distribution to its customers for further manufacture or to manufacture pharmaceutical dosage forms. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Penick Corporation to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Penick Corporation to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 E:\FR\FM\07NON1.SGM 07NON1

Agencies

[Federal Register Volume 72, Number 215 (Wednesday, November 7, 2007)]
[Notices]
[Page 62873]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-21849]



[[Page 62873]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on October 9, 2007, Noramco 
Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by 
renewal to the Drug Enforcement Administration (DEA) to be registered 
as a bulk manufacturer of the basic classes of controlled substances 
listed in schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-Oxide (9053).....................  I
Morphine-N-Oxide (9307)....................  I
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Morphine (9300)............................  II
Thebaine (9333)............................  II
Opium, raw (9600)..........................  II
Opium poppy (9650).........................  II
Oxymorphone (9652).........................  II
Alfentanil (9737)..........................  II
Sufentanil (9740)..........................  II
Carfentanil (9743).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the Schedule I 
controlled substances for internal testing; the Schedule II controlled 
substances will be manufactured in bulk for distribution to its 
customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administrator, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than January 7, 2008.

    Dated: October 31, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-21849 Filed 11-6-07; 8:45 am]
BILLING CODE 4410-09-P